Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
about
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersRibonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotidesAntisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.Therapeutic modulators of STAT signalling for human diseasesTargeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 MiceThe use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse.Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencingAZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.New Modalities for Challenging Targets in Drug Discovery.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.Injection site reactions after subcutaneous oligonucleotide therapyRole of STAT3 in Genesis and Progression of Human Malignant Gliomas.Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?Therapeutic Targeting of Long Non-Coding RNAs in Cancer.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
P2860
Q28821280-195D41EB-5A9A-4584-A7C5-A96711D0E92FQ28828761-83ED8925-995C-483C-AA92-82B2D8E38F6EQ33418637-9C1F4FF1-083B-4029-9AFA-E30368325400Q33574512-32D5A977-684E-443B-B2F4-A2730E29F674Q33684732-8333E539-0E6C-4F93-AC04-213674528956Q33752585-722F712B-7397-4A26-92A1-64CE6C03420FQ35881677-C9B3EEE3-917C-4869-B586-FACE4F977112Q36186164-6EF69E8D-35AE-4FB3-96DE-4559466CCD50Q36711842-27856F49-6BC4-4812-9F41-E06FFCC06BC4Q36755491-FB8A4C54-D70C-4AE3-8911-CB41F0DD82E8Q37031903-0B457B98-B6DE-4231-8D1A-A9824CFE63F4Q37613445-2C5A9EEF-5FBC-446B-837C-CB484A4B87BDQ37633227-135ED2AA-9412-4519-8DAF-A32C2EB4807DQ38289100-BBF88A50-3C72-494C-B3B8-F8500856C325Q38365365-CCF6F006-94C6-4A8B-B5DE-9BED47FB9A2BQ38494470-7992C102-CBEF-4102-942A-CD44FB884A6DQ38504825-6572B20A-C5B7-40DE-BC3C-B8EE1557DBECQ38687571-A7410924-A4EA-43E9-B00A-2AA21327FB75Q38803235-B2FD5EFB-0179-4125-A458-2AE20682AE65Q38962315-A190DA54-C891-450E-A1B9-4CAC238C00DCQ39141872-372E320B-5FA9-4B8B-B4AD-3500FDA6D331Q47605309-3C5C2DFF-9346-429E-AED2-7E573FA1B35FQ49961986-15F11397-FF14-485A-83F2-68A2558CB914Q50191433-26A48013-C229-4BE2-96E7-96E21EC345EA
P2860
Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Preclinical evaluation of the ...... n mice and cynomolgus monkeys.
@en
Preclinical evaluation of the ...... n mice and cynomolgus monkeys.
@nl
type
label
Preclinical evaluation of the ...... n mice and cynomolgus monkeys.
@en
Preclinical evaluation of the ...... n mice and cynomolgus monkeys.
@nl
prefLabel
Preclinical evaluation of the ...... n mice and cynomolgus monkeys.
@en
Preclinical evaluation of the ...... n mice and cynomolgus monkeys.
@nl
P2093
P356
P1476
Preclinical evaluation of the ...... n mice and cynomolgus monkeys.
@en
P2093
A Robert MacLeod
Brett P Monia
Byoung-Seok Lee
Daniel A Norris
Hong-Soo Lee
Scott P Henry
Sebastien A Burel
Shin-Young Park
Shirley Lio
P304
P356
10.1089/NAT.2013.0422
P577
2013-06-01T00:00:00Z